Large genomic rearrangements in the CFTR gene contribute to CBAVD by Taulan, Magali et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Medical Genetics
Open Access Research article
Large genomic rearrangements in the CFTR gene contribute to 
CBAVD
Magali Taulan1,2,3, Anne Girardet1,2,3, Caroline Guittard3, Jean-Pierre Altieri3, 
Carine Templin3, Christophe Beroud1,2,3, Marie des Georges1,3 and 
Mireille Claustres*1,2,3
Address: 1INSERM, U 827, Montpellier, F-34000 France, 2Université Montpellier1, UFR de Médecine, laboratoire de GénétiqueMoléculaire, 
Montpellier, F-3400 France and 3CHU Montpellier, hôpital Arnaud de Villeneuve, laboratoire de Génétique Moléculaire, Montpellier, F-34000 
France
Email: Magali Taulan - magali.taulan@montp.inserm.fr; Anne Girardet - anne.girardet@montp.inserm.fr; 
Caroline Guittard - caroline.guittard@montp.inserm.fr; Jean-Pierre Altieri - jean-pierre.altieri@montp.inserm.fr; 
Carine Templin - carine.templin@montp.inserm.fr; Christophe Beroud - christophe.beroud@montp.inserm.fr; Marie des 
Georges - marie.desgeorges@montp.inserm.fr; Mireille Claustres* - mireille.claustres@montp.inserm.fr
* Corresponding author    
Abstract
Background: By performing extensive scanning of whole coding and flanking sequences of the
CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, we had previously identified point
mutations in 167 out of 182 (91.7%) males with isolated congenital bilateral absence of the vas
deferens (CBAVD). Conventional PCR-based methods of mutation analysis do not detect gross
DNA lesions. In this study, we looked for large rearrangements within the whole CFTR locus in the
32 CBAVD patients with only one or no mutation.
Methods: We developed a semi-quantitative fluorescent PCR assay (SQF-PCR), which relies on
the comparison of the fluorescent profiles of multiplex PCR fragments obtained from different
DNA samples. We confirmed the gross alterations by junction fragment amplification and identified
their breakpoints by direct sequencing.
Results: We detected two large genomic heterozygous deletions, one encompassing exon 2 (c.54-
5811_c.164+2186del8108ins182) [or CFTRdele2], the other removing exons 22 to 24 (c.3964-
3890_c.4443+3143del9454ins5) [or CFTRdele 22_24], in two males carrying a typical CBAVD
mutation on the other parental CFTR allele. We present the first bioinformatic tool for exon
phasing of the CFTR gene, which can help to rename the exons and the nomenclature of small
mutations according to international recommendations and to predict the consequence of large
rearrangements on the open reading frame.
Conclusion: Identification of large rearrangements further expands the CFTR mutational spectrum
in CBAVD and should now be systematically investigated. We have designed a simple test to
specifically detect the presence or absence of the two rearrangements identified in this study.
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Background
Congenital bilateral absence of the vas deferens (CBAVD)
accounts for approximately 3% of cases of male infertility
in Caucasian populations. In about 85% of cases, CBAVD
is recognized as an autosomal recessive disorder
(MIM≠277180) associated with mutations in the cystic
fibrosis transmembrane conductance regulator gene
(CFTR, also symbolized ABCC7) [1-3]. Almost all of
1,500 different mutations so far identified in the CFTR
gene in cystic fibrosis (CF) (MIM≠219700) or in related
disorders (updates in the Cystic Fibrosis Mutation Data-
base [4]) are single-nucleotide changes or small base
pair(s) insertions or deletions in the exons or their flank-
ing intronic sequences. The CFTR gene encodes a protein
expressed in the apical membrane of exocrine epithelial
cells which functions principally as a cAMP induced chlo-
ride channel and regulates also other ion channels. A
combination of severe genetic changes in the two CFTR
alleles that reduces CFTR function below 5% of physio-
logical levels usually leads to the severe forms of classical
CF [5,6]. Other so-called mild mutations that retain
higher CFTR residual function can cause milder or incom-
plete phenotypes or CFTR-associated phenotypes. CBAVD
is caused either by two mild mutations or by a severe and
a mild mutation [3,7,8]. Routine testing for the most prev-
alent mutations in classical CF misses most CFTR gene
alterations in the CBAVD phenotype, which can be
detected only by scanning the 27 CFTR coding and flank-
ing sequences [8,9]. However, despite exhaustive analysis
of the CFTR gene, a proportion of mutations still remains
unidentified in CBAVD, ranging from 15 to 40% depend-
ing both on the technologies used and the ethnicity of
patients.
Recent studies in cases with classical cystic fibrosis sug-
gested that gross rearrangements encompassing a single or
several exons could account for a significant part of uni-
dentified alleles. Large deletions have been discovered
either fortuitously on the basis of uniparental inheritance
of polymorphic markers [10-14] and Southern blotting
[15] or through a systematic screening [16-19]. These
mutations, when present at the heterozygous state, elude
the PCR-based techniques designed to detect small DNA
alterations.
In CBAVD, there is paucity of information about large
genomic rearrangements and only two have been reported
so far but without information on breakpoints sequences
[17,20].
In this study, we used a semi-quantitative fluorescent mul-
tiplex PCR assay to screen samples from CBAVD patients
that remained unresolved after extensive scanning of
CFTR  exons. Two large deletions have been identified,
which further confirms the involvement of gross DNA
alterations in CBAVD.
Methods
Nomenclature of mutations
We followed the international nomenclature guidelines
recommended in the Human Genome Variation Society
web page [21]. However, for convenience to readers used
to the nomenclature of the Cystic Fibrosis Mutation Data-
base [4], the usual names of mutations are also indicated
[in italic and in brackets].
Recruitment of CBAVD Samples with One or No CFTR 
mutation
Our current procedure to detect CFTR point mutations
responsible for CBAVD includes the following steps: 1)
the screening for 33 common CF mutations by using a
commercial kit (CF OLA assay, Abbot, Rungis-France), 2)
the scanning of all 27 exons and their intronic boundaries
by using optimized laboratory DGGE (Denaturing Gradi-
ent Gel Electrophoresis) or dHPLC (denaturing High Pressure
Liquide phase Chromatography) protocols, 3) the sequenc-
ing of any abnormal region to confirm and characterize
the sequence change by using ABI Prism BigDye Termina-
tor Cycle Sequencing kit (PE Applied Biosystems). In
addition, we also screen DNAs for intronic splicing muta-
tions c.1679+1634A>G [1811+1.6KbA>G] and
c.3717+10kbC>T [3849+10kbC>T] using PRC-restriction
with appropriate enzymes. The whole procedure has been
previously applied to each of the 182 unrelated patients
with documented CBAVD who have been referred to our
lab so far, allowing us to detect one or two CFTR muta-
tions in 167 of them [[8] and unpublished results]. Here
we have further studied the 32 samples remaining with
one (n = 17) or no (n = 15) mutation. Whenever possible,
we studied the familial segregation of mutations and var-
iations in order to determine whether sequence changes
were located on a single or on the two parental CFTR alle-
les. Informed consent to CFTR studies had been previ-
ously obtained from patients and relatives at the time of
referral.
Search of Gross Rearrangements in the CFTR Gene by 
SQF-PCR Analysis
We used a semi-quantitative fluorescent multiplex PCR
assay (SQF-PCR) developed in our laboratory for the
detection of exon deletions and duplications in the CFTR
gene. The method relies on the comparison of the fluores-
cent profiles of multiplex PCR fragments obtained from
different samples, the amplification being stopped at the
exponential phase. The 27 exons were grouped into three
multiplex PCRs with one primer of each pair 5'-labeled
with the 6-FAM fluorochrome (oligonucleotide primers
available upon request). Amplification mixture included
5 to 20 pmol of each primer and 150 ng of genomic DNABMC Medical Genetics 2007, 8:22 http://www.biomedcentral.com/1471-2350/8/22
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in a 20 μl volume. Concentration and quality of DNAs
were thoroughly determined prior amplification reac-
tions. The PCR cycling conditions were selected using
QIAGEN Multiplex PCR Kit according to the manufac-
turer's instructions (Qiagen, Courtaboeuf, France).
Amplifications were performed with an initial denatura-
tion step at 95°C for 15 min, followed by 20 cycles of 30
s at 95°C denaturation, 90 s at 57°C annealing and 1 min
extension at 72°C, followed by a final extension at 72°C
for 10 min, using a Gene Amp 9700 Thermal Cycler
(Applied Biosystems, Foster City, CA). Amplified DNA
fragments were separated on an ABI 310 or 3130xl
sequencer at 60°C. Using Genescan and Genotyper (ABI
310) or GeneMapper (ABI 3130xl) softwares, the data
were analyzed by superimposing fluorescent profiles of
test and control DNAs and by calculating dosage quotient
for area and height of all peaks [22] after normalization
with an exon of the DMD gene.
Confirmation of Deletions by Junction Fragment 
Amplification
We developed a simple and rapid test to confirm the iden-
tified deletions using two distinct duplex PCRs. For muta-
tion c.54-5811_c.164+2186del8108ins182 [CFTRdele2],
one pair of primers [23] amplifies wild type exon 2 while
the other one has been designed to detect specifically the
deleted allele [primers IVS1F (5'-TACACAAGGCTT-
GTCTTTAG-3') and IVS2R (5'GTTAAGCCAGATAAT-
TCTGC-3'  (this study)]. For mutation c.3964-
3890_c.4443+3143del9454ins5 [CFTRdele22_24], we
used one pair of primers to amplify wild type exon 22 [23]
and primers IVS21-3940F and TAG+3303R [15] to detect
the junction fragment of the deletion. PCR products were
separated by electrophoresis on a 2% agarose gel and vis-
ualized by ethidium bromide staining. This test ensures
an internal amplification control and can distinguish
between homozygous and heterozygous samples for the
deletion.
Identification of Breakpoints
We characterized the two large rearrangements by
sequencing the amplified fragments of genomic DNA
encompassing the breakpoints using primers noted
above.
Computer-Assisted Sequence Analysis
Large portions of genomic DNA sequences within and
around the rearrangements were searched for both low
complexity/simple repeats and interspersed repeats using
the RepeatMasker program and were analyzed for sequence
similarity using the BLAST tool available through UCSC
(University of California Santa Cruz) Genome Browser on
Human (March 2006 assembly) [24]. To predict the effect
of large deletions on the CFTR  open reading frame
sequences, we used the "exon-phasing tool" of the UMD®
software (Universal Mutation Database) [25,26], which
gives access to a graphical presentation of all coding exons
of a gene according to their phasing in order to predict, at
least at the genomic level, the consequence of the deletion
of one or more exons on the open reading frame of the
CFTR gene.
Results
Using a comprehensive CFTR gene analysis protocol we
had previously identified CFTR  mutations in 167/182
(91.7%) patients with documented CBAVD including 150
(82.4%) with two mutations and 17 (9.3%) with one
mutation. In the current study we present the result of our
investigations concerning the involvement of large rear-
rangements in the 32 remaining samples with one or no
CFTR small mutation.
Detection of two Complex CFTR Large Deletions and 
Confirmation of Deletion Breakpoint Junctions
Using SQF-PCR, a large genomic deletion was identified
in 2 (6.25%) of the 32 samples analyzed in this study.
Rearrangement c.54-5811_c.164+2186del8108ins182
[CFTRdele2] (Figure 1A) was found in a 27-year-old
patient originating from Southern Italia carrying on the
other allele the typical CBAVD splice variant
IVS8(TG)12T(5). Rearrangement c.3964-
3890_c.4443+3143del9454ins5 [CFTRdele22_24] (Fig-
ure 1B) was found in a 41-year-old man with Spanish and
Sicily background carrying the missense mutation
p.Arg170His. Both large deletions were found to be asso-
ciated with a 7T allele at the IVS8(Tn) locus. The presence
of either of the two deletions was confirmed by specific
duplex PCRs amplifying both wild-type and deleted alle-
les in heterozygote samples. DNA sequencing showed that
deletions breakpoint junctions appeared to be the same as
those recently described in two patients with cystic fibro-
sis as IVS1-5811_IVS2+2186del8108ins182 [27] or
IVS21-3890_Stop+3143del9454ins5 [15].
Analysis of Genomic Sequences and Exon Phasing of the 
CFTR Gene
Despite the presence of Interspersed repeat elements in
the vicinity of the rearrangements (Figure 1), there is no
significant homology flanking the deletion breakpoints or
insertion junctions to suggest that homologous recombi-
nation has occurred.
The "exon-phasing tool" of the UMD® software [25] uses a
numerotation of CFTR exons in accordance with interna-
tional nomenclatures and predicts an in-frame deletion of
exon 2 (36 amino acids) for mutation c.54-
5811_c.164+2186del8108ins182 [CFTRdele2] and the
loss of the three last CFTR coding sequences (exons 22 to
24, that should be numbered 25 to 25, totalizing 159
amino acids) for mutation c.3964-BMC Medical Genetics 2007, 8:22 http://www.biomedcentral.com/1471-2350/8/22
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A) Confirmation of complex deletion c.54-5811_c.164+2186del8108ins182 [CFTRdele2] in CBAVD Figure 1
A) Confirmation of complex deletion c.54-5811_c.164+2186del8108ins182 [CFTRdele2] in CBAVD. Rearrange-
ment c.54-5811_c.164+2186del8108ins182 (upper panel) consists of a gross deletion of 8108 bp spanning exon 2 (dotted area) 
and an insertion of 182 bp (grey area) at the deletion junction between the nucleotide 54-5811 of intron 1 (IVS1 nt 18294) and 
the nucleotide 164+2186 of intron 2 (IVS2 nt 2186) [according to the recommended international nomenclature with the A of 
the ATG start codon numbered as +1]. The 182-bp insertion is part of intron 3 between IVS3 nucleotides 6780 and 6961 but 
in inverted orientation (arrow). This complex in/del is also termed c.186-5811_c.296+2186del8108+ins182 with the A of the 
ATG translation start codon numbered as +133 in accordance with the GenBank reference sequence for the CFTR gene on 
chromosome 7 (NM_000492.2) and the CF mutation database [4]. It was recently reported as IVS1-
5811_IVS2+2186del8108ins182 in one patient with cystic fibrosis [27]. A specifically-designed junction fragment amplification 
test (lower panel) confirmed the presence of the heterozygous deletion, indicated by specific PCR products on 2% agarose gels 
(left) by comparison with the non deleted allele. The deletion breakpoint junctions (indicated by vertical bars) and inserted 
sequences were determined by direct sequencing (right). B) Confirmation of complex deletion c.3964-
3890_c.4443+3143del9454ins5 [CFTRdele22_24 or CFTRdele25_27] in CBAVD. Rearrangement c.3964-
3890_c.4443+3143del9454ins5 (upper panel) consists of a gross deletion of 9454 bp (dotted area) encompassing exons 25 to 
27 [22 to 24], the stop codon and the poly(A) signal. A small insertion of 5 bases (TAACT) was observed at the junction but is 
too small to allow any determination of its origin (arrow). The same rearrangement has recently been described in one patient 
with cystic fibrosis as c.4096-3890_c.4575+3143del9454ins5 with the A of the ATG translation start codon numbered as +133 
in accordance with the GenBank reference sequence for the CFTR gene on chromosome 7 (NM_000492.2) or as IVS21-
3890Stop+3143del9454insTAACT [15]. A specifically-designed junction fragment amplification test (lower panel) confirmed the 
presence of the heterozygous deletion, indicated by specific PCR products on 2% agarose gels (left) by comparison with the 
non deleted allele. The deletion breakpoint junctions (indicated by vertical bars) and inserted sequences were determined by 
direct sequencing (right).
A
B
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3890_c.4443+3143del9454ins5 [CFTRdele22_24] (Fig-
ure 2).
Discussion
Despite the accumulated information about genomic
rearrangements in patients with cystic fibrosis, where they
account for up to 16 to 24% of CF alleles negative for
point mutations in European populations [15-18][27],
only two large exonic rearrangements have been described
so far in CBAVD [17,20]. The SQF-PCR protocol described
in the present study enables the rapid and reliable detec-
tion of unknown CFTR gene deletions or duplications in
CF or CBAVD. We identified two large rearrangements in
two males carrying a typical CBAVD mutation on the
other parental CFTR  allele in a sample of 32 patients,
which elucidates 4.25% of alleles that remained unidenti-
fied after standard investigations for point mutations. The
remaining unsolved alleles might be explained by muta-
tions in CFTR  non-coding regions not explored by
genomic DNA-based available methods or by the contri-
bution of other(s) gene(s) to CBAVD. However if we pos-
tulate that, for most of the 15 patients with no mutation,
CBAVD is probably not linked to CFTR defects, large rear-
rangements could represent 12% (2/17 alleles) of uniden-
tified alleles, which is in the range of figures observed in
the CF population. With this hypothesis, searching for
large rearrangements in addition to conventional geno-
typing would identify two mutations in 152/167 (91%)
and one mutation in 15/167 (9%) of CBAVD males. The
two deletions found in our CBAVD samples are predicted
to be "severe" alleles precluding the production of a func-
tional CFTR protein and are thus null mutations. Bioin-
formatic analysis of the sequences flanking large
rearrangements in the CFTR  gene suggest that non-
homologous end joining [28] is the most likely mecha-
nism that is responsible for their occurrence, in accord-
ance with recent studies [17,27].
Conclusion
Screening for large genomic rearrangements in the CFTR
gene is beneficial not only in classical cystic fibrosis but
also in CBAVD, especially for those males who are carriers
of a CFTR  mild mutation. This study strengthens the
importance to include screening of gross rearrangements
in CFTR mutations scanning to offer adequate diagnosis
and genetic counselling for CBAVD couples. International
numerotation of exons should be used in order to avoid
future misdiagnosis.
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Exon phasing of the CFTR gene (Universal Mutation Database [25]). The CFTR gene comprises 27 exons which were 
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